Patient-Specific Microfluidic Cancer Spheroid Cultures for Testing Cancer Therapies.
Patient-Specific Microfluidic Cancer Spheroid Cultures for Testing Cancer Therapies.
复制标题
用于测试癌症治疗的患者特异性微流体癌症球体培养物。
DOI：
10.1007/978-1-0716-3271-0_15
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Revzin,Alexander
中科院分区：
文献类型：
--
作者：
Choi,Daheui;Gonzalez-Suarez,AlanM;Billadeau,DanielD;Ma,WenWee;Stybayeva,Gulnaz;Revzin,Alexander
肿瘤学领域越来越注重在患者基础上预测给定治疗的有效性的策略。这种精确或个性化的肿瘤学有可能显著延长患者的生存时间。患者衍生的有机化合物被视为患者肿瘤组织的主要来源，可用于个性化肿瘤学的治疗测试。培养癌症类器官的黄金标准方法是在涂有Matrigel的标准多孔板中培养。尽管它们有效，但这些标准的类有机物培养有缺点，即需要大量的起始细胞群和癌症类有机物大小的多分散性。后者的缺点使监测和量化治疗后类器官大小的变化变得具有挑战性。具有集成的微孔阵列的微流控装置可用于减少形成有机物所需的起始细胞材料的量，并标准化有机物的大小以使治疗评估更容易。在这里，我们描述了制造微流控设备以及种植患者来源的癌细胞、培养有机物和使用这些设备测试治疗方法的方法。
The field of oncology increasingly focuses on strategies to predict effectiveness of a given therapy on a patient-by-patient basis. Such precision or personalized oncology has the potential of significantly extending patient survival time. Patient-derived organoids are seen as the main source of patient tumor tissue that may be used for therapy testing in personalized oncology. The gold standard approach for culturing cancer organoids is in standard multi-well plates coated with Matrigel. Despite their effectiveness, these standard organoid cultures have drawbacks, namely, requirement of a large starting cell population and polydispersity of cancer organoid sizes. The latter drawback makes it challenging to monitor and quantify changes in organoid size in response to therapy. Microfluidic devices with integrated arrays of microwells may be used to both decrease the amount of starting cellular material required to form organoids and to standardize organoid size to make therapy assessment easier. Herein, we describe methodology for making microfluidic device as well as for seeding patient-derived cancer cells, culturing organoids, and testing therapies using these devices.